Back
Revance Therapeutics 10K Form
Sell
13
RVNC
Revance Therapeutics
Last Price:
3.71
Seasonality Move:
7.02%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
10K form not available
Receive RVNC News And Ratings
See the #1 stock for the next 7 days that we like better than RVNC
RVNC Financial Statistics
Sales & Book Value
Annual Sales: | $234.04M |
---|---|
Cash Flow: | $-38.14M |
Price / Cash Flow: | 0 |
Annual Sales: | $-1.24 |
Price / Book: | 0 |
Profitability
EPS (TTM): | -3.20000 |
---|---|
Net Income (TTM): | $-287.5M |
Gross Margin: | $159.68M |
Return on Equity: | 0% |
Return on Assets: | -55.05% |
Revance Therapeutics Earnings Forecast
Key Revance Therapeutics Financial Ratios
- The Gross Profit Margin over the past 13 years for RVNC is 68.23%.
- The Selling, General & Administrative Expenses for RVNC have been equal to 124.87% of Gross Profit Margin.
- The Research & Development expenses have been 33.93% of Revenue.
- The Interest Expense is -5.97% of Operating Income.
- The Net Earning history of RVNC is -138.43% of Total Revenues.
- Per Share Earnings over the last 13 years have been positive in 6 years.
Revance Therapeutics Stock Price Chart
Industry, Sector and Symbol
Stock Exchange: | NASDAQ |
---|---|
Industry: | Pharmaceuticals |
Sector: | Health Care |
Current Symbol: | RVNC |
CUSIP: | 761330 |
Website: | revance.com |
Debt
Debt-to-Equity Ratio: | -3.32 |
---|---|
Current Ratio: | 3.74 |
Quick Ratio: | 2.87 |
Price-to-Earnings
Trailing P/E Ratio: | 0 |
---|---|
Forward P/E Ratio: | 0 |
RVNC Technical Analysis vs Fundamental Analysis
Sell
13
Revance Therapeutics (RVNC)
is a Sell
Is Revance Therapeutics a Buy or a Sell?
-
Revance Therapeutics stock is rated a Sell
The current Revance Therapeutics [RVNC] share price is $3.71. The Score for RVNC is 13, which is 74% below its historic median score of 50, and infers higher risk than normal.